CervoMed (CRVO)
Search documents
Diffusion Pharmaceutical (DFFN) Presents At HC Wainwright Global Life Sciences Conference
2021-03-14 13:23
| --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | <'$-'=0*/>>< | | | | | | | | /(889$()%* !2'":',#9&(,';$ Enhancing Oxygen, Fueling Life | | | | | | | | Corporate Presentation for HC Wainwright Global Life Sciences Conference March 9-10, 2021 | | | | | | | | !"#$#%&'&()%* +#,)"-(%.*/' 1'",2*34*5657 | | | | Note Regarding Forward-Look ...
CervoMed (CRVO) - 2020 Q3 - Quarterly Report
2020-11-12 22:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delawa ...
CervoMed (CRVO) - 2020 Q2 - Quarterly Report
2020-08-07 20:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 30 ...
CervoMed (CRVO) - 2020 Q1 - Quarterly Report
2020-05-11 20:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 3 ...
CervoMed (CRVO) - 2019 Q4 - Annual Report
2020-03-17 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact Name of Registrant as specified in its Charter) | --- | --- | --- | |------------------- ...
CervoMed (CRVO) - 2019 Q3 - Quarterly Report
2019-11-08 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delawa ...
CervoMed (CRVO) - 2019 Q2 - Quarterly Report
2019-08-08 20:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark one) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 30 ...
CervoMed (CRVO) - 2019 Q1 - Quarterly Report
2019-05-09 20:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark one) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 000-24477 DIFFUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 3 ...
CervoMed (CRVO) - 2018 Q4 - Annual Report
2019-03-19 18:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------|-------------------------------------------| | For the transition period from | to | | Commission fi ...